Google’s Latest Partnership Could Revolutionize Genome Analysis!

On Wednesday, Google (NASDAQ: GOOGL) quietly added an 800-pound gorilla to its arsenal.

Google Genomics, the company’s cloud-computing platform for life science research, added a tool called the Genome Analysis Toolkit (or GATK), which was developed by the Broad Institute of MIT and Harvard.

This amazing piece of software will help scientists quickly analyze genome-sequencing data. Before, this information was sectioned off in academic labs across the country. But as a service, it’s now online for academic researchers to use for free.

The best part however isn’t the accessibility, but all the possibilities that partnering with Google will offer.

The Genome Analysis Toolkit will now run on Google’s very powerful cloud-computing infrastructure, giving it the horsepower it needs to crunch the massive data sets of human genomic data — fast.

Sequencing human DNA generates colossal amounts of data. It’s like 100 gigabytes per person. The basic model for iPhone 6 only has 16! So for researchers, this is big news!

To date, the Broad Institute has either sequenced or genotyped the equivalent of more than 1.4 million biological samples. That’s a whole lot of data to have readily accessible! With the Google partnership, the Institute can now focus on its research without having to worry about managing IT infrastructure.

This trend in outsourcing the infrastructure of DNA processing is picking up across the biotech industry. Besides Google, there are several other companies starting to make a splash in this arena.

For my BioTech Intel Trader readers, that means opportunities to profit from the market plays behind this igniting industry… and many others in the health and biotech sectors.

You can get in on the action here.

Image Signature

Ben Benoy
Editor, BioTech Intel Trader

Harry Dent’s Most Disturbing Prediction in Years

Harry Dent, one of the most respected economists in the industry, has uncovered a disturbing market event that could soon devastate millions of investors. In short, he has undeniable proof that one of the market’s safest and most popular investments is about to get slaughtered… and it will have dire consequences for those who don’t prepare right away.

For full details on the event Harry’s dubbed as the “Safe-Asset Slaughter”… and to ensure you escape the coming carnage, I urge you to watch this special presentation.

Click to Learn More
Categories: Biotech

About Author

Ben Benoy is a veteran of the U.S. Marine Corps and has been an active retail trader since 2006. He identifies investment opportunities based on key social media trends. He first identified the concept in 2008 and has since developed a tool for tracking investment “chatter” between social media users. His proprietary Social Media Stock Sentiment system has developed into a state-of-the-art platform that identifies and classifies chatter about stocks through algorithms and other indicators to forecast stock-price direction. Ben’s track record speaks for itself — over the past 12 months, his system boasts a win rate of 82.2% on 112 stock trades.